Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NSD2 | O96028 | 2/20 | 0.98 |
| ▸ | PABPC1 | P11940 | 2/20 | 0.98 |
| ▸ | CASP6 | P55212 | 1/20 | 0.98 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.98 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | BCL2A1 | Q16548 | 1/20 | 0.39 |
| ▸ | CDC25B | P30305 | 1/20 | 0.39 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.36 |
| ▸ | DRD2 | P14416 | 2/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.36 |
| ▸ | DRD4 | P21917 | 2/20 | 0.36 |
| ▸ | HRH2 | P25021 | 2/20 | 0.36 |
| ▸ | HTR2A | P28223 | 2/20 | 0.36 |
| ▸ | HTR7 | P34969 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13856939 | 0.69 | NSD2 (0.52) | NSD2PABPC1CASP6PAX8KDM4E | |
| SCHEMBL4905012 | 0.67 | HTR1A (0.54) | NSD2PABPC1CASP6PAX8KDM4E | |
| SCHEMBL8966405 | 0.67 | — | — | |
| SCHEMBL20842260 | 0.66 | HTR1A (0.51) | NSD2PABPC1CASP6PAX8KDM4E | |
| SCHEMBL31305373 | 0.66 | MEN1 (0.55) | NSD2PABPC1CASP6PAX8KDM4E | |
| SCHEMBL31305372 | 0.66 | MEN1 (0.55) | NSD2PABPC1CASP6PAX8KDM4E | |
| SCHEMBL11104593 | 0.64 | KDM4E (0.52) | NSD2PABPC1CASP6PAX8KDM4E | |
| SCHEMBL3431530 | 0.64 | HTR1A (0.51) | NSD2PABPC1CASP6PAX8KDM4E | |
| SCHEMBL22266161 | 0.64 | KCNH2 (0.62) | HTR1ACHRM2ADRA2ADRD2ADRA2B | |
| SCHEMBL27773031 | 0.64 | HTR1A (0.45) | NSD2PABPC1CASP6PAX8KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150148292-A1 | BONE MORPHOGENETIC PROTEIN PATHWAY ACTIVATION, COMPOSITIONS FOR OSSIFICATION, AND METHODS RELATED THERETO | UNIV EMORY (US) | 2015-05-28 | — | — | US | claimed |
| US-10933169-B2 | Bone morphogenetic protein pathway activation, compositions for ossification, and methods related thereto | EMORY UNIVERSITY (US) | 2021-03-02 | — | — | US | disclosed |
| US-10434220-B2 | Bone morphogenetic protein pathway activation, compositions for ossification, and methods related thereto | EMORY UNIVERSITY (US) | 2019-10-08 | — | — | US | disclosed |
| US-20160089478-A1 | BONE MORPHOGENETIC PROTEIN PATHWAY ACTIVATION, COMPOSITIONS FOR OSSIFICATION, AND METHODS RELATED THERETO | UNIV EMORY (US) | 2016-03-31 | — | — | US | disclosed |
| US-20150148292-A1 | BONE MORPHOGENETIC PROTEIN PATHWAY ACTIVATION, COMPOSITIONS FOR OSSIFICATION, AND METHODS RELATED THERETO | UNIV EMORY (US) | 2015-05-28 | — | — | US | disclosed |
| US-20150148292-A1 | BONE MORPHOGENETIC PROTEIN PATHWAY ACTIVATION, COMPOSITIONS FOR OSSIFICATION, AND METHODS RELATED THERETO | UNIV EMORY (US) | 2015-05-28 | — | — | US | disclosed |
| WO-2014011540-A1 | BONE MORPHOGENETIC PROTEIN PATHWAY ACTIVATION, COMPOSITIONS FOR OSSIFICATION, AND METHODS RELATED THERETO | EMORY UNIVERSITY (US) | 2014-01-16 | — | — | WO | disclosed |
| WO-2014011540-A1 | BONE MORPHOGENETIC PROTEIN PATHWAY ACTIVATION, COMPOSITIONS FOR OSSIFICATION, AND METHODS RELATED THERETO | EMORY UNIVERSITY (US) | 2014-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150148292-A1 | BONE MORPHOGENETIC PROTEIN PATHWAY ACTIVATION, COMPOSITIONS FOR OSSIFICATION, AND METHODS RELATED THERETO | BMP4, BMP2, BMP1 | NSD2 3971/4885PABPC1 1723/4885CASP6 755/4885 |
| US-10434220-B2 | Bone morphogenetic protein pathway activation, compositions for ossification, and methods related thereto | BMP2, BMP4, BMP1 | NSD2 4395/4885PABPC1 2474/4885CASP6 1947/4885 |
| US-10933169-B2 | Bone morphogenetic protein pathway activation, compositions for ossification, and methods related thereto | BMP2, BMP4, BMP1 | NSD2 4395/4885PABPC1 2474/4885CASP6 1947/4885 |
| US-20160089478-A1 | BONE MORPHOGENETIC PROTEIN PATHWAY ACTIVATION, COMPOSITIONS FOR OSSIFICATION, AND METHODS RELATED THERETO | BMP2, BMP4, BMP1 | NSD2 4395/4885PABPC1 2474/4885CASP6 1947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.